SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Tong S.) srt2:(2015-2019)"

Search: WFRF:(Tong S.) > (2015-2019)

  • Result 1-10 of 62
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  • Ruilope, LM, et al. (author)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • In: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Journal article (peer-reviewed)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
5.
  • 2019
  • Journal article (peer-reviewed)
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Vicedo-Cabrera, A. M., et al. (author)
  • Temperature-related mortality impacts under and beyond Paris Agreement climate change scenarios
  • 2018
  • In: Climatic Change. - : Springer. - 0165-0009 .- 1573-1480. ; 150:3-4, s. 391-402
  • Journal article (peer-reviewed)abstract
    • The Paris Agreement binds all nations to undertake ambitious efforts to combat climate change, with the commitment to “hold warming well below 2 °C in global mean temperature (GMT), relative to pre-industrial levels, and to pursue efforts to limit warming to 1.5 °C”. The 1.5 °C limit constitutes an ambitious goal for which greater evidence on its benefits for health would help guide policy and potentially increase the motivation for action. Here we contribute to this gap with an assessment on the potential health benefits, in terms of reductions in temperature-related mortality, derived from the compliance to the agreed temperature targets, compared to more extreme warming scenarios. We performed a multi-region analysis in 451 locations in 23 countries with different climate zones, and evaluated changes in heat and cold-related mortality under scenarios consistent with the Paris Agreement targets (1.5 and 2 °C) and more extreme GMT increases (3 and 4 °C), and under the assumption of no changes in demographic distribution and vulnerability. Our results suggest that limiting warming below 2 °C could prevent large increases in temperature-related mortality in most regions worldwide. The comparison between 1.5 and 2 °C is more complex and characterized by higher uncertainty, with geographical differences that indicate potential benefits limited to areas located in warmer climates, where direct climate change impacts will be more discernible.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 62
Type of publication
journal article (50)
conference paper (9)
research review (3)
Type of content
peer-reviewed (61)
other academic/artistic (1)
Author/Editor
Fu, S (7)
Tang, M (7)
Liu, D. (6)
Yang, J. (6)
Forsberg, Bertil (6)
Popov, Sergei (6)
show more...
Pang, Xiaodan, Dr. (6)
Chen, Jiajia (5)
Shen, CY (5)
Tong, L (5)
Ahsan, H (5)
Ozolins, Oskars (5)
Scortichini, Matteo (5)
Pascal, Mathilde (5)
Gasparrini, Antonio (5)
Schwartz, Joel (5)
Sera, Francesco (5)
Bell, Michelle L (5)
Guo, Yuming (5)
Hashizume, Masahiro (5)
Honda, Yasushi (5)
Íñiguez, Carmen (5)
Kan, Haidong (5)
Kim, Ho (5)
Lavigne, Eric (5)
Ragettli, Martina S (5)
Tobias, Aurelio (5)
Tong, Shilu (5)
Zanobetti, Antonella (5)
Wang, J. (4)
Zhang, H. (4)
Zhang, Y. (4)
Lee, E. (4)
Kim, S. (4)
Wang, L (4)
Chen, J. (4)
Lee, B. (4)
Sun, Y (4)
Jain, M (4)
Isaksson, Hanna (4)
Jin, L (4)
Dumitrescu, A (4)
Michelozzi, Paola (4)
Armstrong, Ben (4)
Vicedo-Cabrera, Ana ... (4)
Chen, Bing-Yu (4)
Dang, Tran Ngoc (4)
Kyselý, Jan (4)
Seposo, Xerxes (4)
Urban, Aleš (4)
show less...
University
Karolinska Institutet (26)
Royal Institute of Technology (12)
Lund University (11)
Uppsala University (10)
Umeå University (8)
University of Gothenburg (7)
show more...
Linköping University (5)
RISE (5)
Stockholm University (4)
Chalmers University of Technology (4)
Halmstad University (2)
Luleå University of Technology (1)
Stockholm School of Economics (1)
Södertörn University (1)
show less...
Language
English (62)
Research subject (UKÄ/SCB)
Medical and Health Sciences (27)
Natural sciences (22)
Engineering and Technology (9)
Social Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view